A new study by researchers from the London School of Hygiene and Tropical Medicine, Cambridge University and the Karolinska Institute in Sweden has found that even light or moderate intensity physical activity, such as walking or cycling, can substantially reduced the risk of early death. Continue Reading
A new study by researchers from the London School of Hygiene and Tropical Medicine, Cambridge University and the Karolinska Institute in Sweden has found that even light or moderate intensity physical activity, such as walking or cycling, can substantially reduced the risk of early death. Continue Reading
A new study by researchers from the London School of Hygiene and Tropical Medicine, Cambridge University and the Karolinska Institute in Sweden has found that even light or moderate intensity physical activity, such as walking or cycling, can substantially reduced the risk of early death. Continue Reading
A new study by researchers from the London School of Hygiene and Tropical Medicine, Cambridge University and the Karolinska Institute in Sweden has found that even light or moderate intensity physical activity, such as walking or cycling, can substantially reduced the risk of early death. Continue Reading
A new study by researchers from the London School of Hygiene and Tropical Medicine, Cambridge University and the Karolinska Institute in Sweden has found that even light or moderate intensity physical activity, such as walking or cycling, can substantially reduced the risk of early death. Continue Reading
A new study by researchers from the London School of Hygiene and Tropical Medicine, Cambridge University and the Karolinska Institute in Sweden has found that even light or moderate intensity physical activity, such as walking or cycling, can substantially reduced the risk of early death. Continue Reading
A new system that utilizes a precise a GPS-like system to track prostate cancer tumors is now being offered to patients undergoing radiation therapy at Cedars-Sinai’s Samuel Oschin Comprehensive Cancer Institute. The monitoring system, called Calypso, allows radiation beams to more precisely target the cancer as it gives real-time positioning information that allows the radiation beams to focus directly on the cancer. Continue Reading
Forest Laboratories, Inc. Forest Laboratories Holdings, Ltd., Merz Pharma GmbH & Co. KGaA, and Merz Pharmaceuticals GmbH announced today that they have entered into settlement agreements with all remaining defendants in patent infringement litigation related to Forest’s NAMENDA® (memantine hydrochloride) immediate release tablets. Continue Reading
Johnson and Johnson’s experimental HIV drug rilpivirine or TMC278, a non-nucleoside reverse transcriptase inhibitor (NNRTI), is being developed for use in combination therapy for treating the human immunodeficiency virus (HIV) that causes AIDS. Two clinical trials with the drug has shown that although its effectiveness was same as the existing anti-HIV drugs, its side effects were fewer. On the flip side nearly twice as many patients failed to respond to treatment with the new drug. Continue Reading
Tibotec Pharmaceuticals announced today results from two pivotal Phase 3, double-blind, randomized clinical trials comparing the efficacy, safety and tolerability of its investigational non-nucleoside reverse transcriptase inhibitor (NNRTI) TMC278 (rilpivirine) versus efavirenz (EFV), each administered once daily with a nucleoside/nucleotide background regimen in treatment-naive, HIV-1-infected adults. Continue Reading
